LYEL VS TYRA Stock Comparison

Performance

LYEL
10/100

LYEL returned -58.96% in the last 12 months. Based on SPY's performance of -13.12%, its performance is below average giving it a score of 10 of 100.

TYRA
100/100

TYRA returned 64.62% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Technicals

LYEL
54/100

LYEL receives a 53 of 100 based on 14 indicators. 7 are bullish, 6 are bearish.

TYRA
36/100

TYRA receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Earnings

LYEL
100/100

LYEL has missed earnings 1 times in the last 20 quarters.

TYRA
10/100

TYRA has missed earnings 4 times in the last 20 quarters.

Profit

LYEL
10/100

Out of the last 15 quarters, LYEL has had 0 profitable quarters and has increased their profits year over year on 0 of them.

TYRA
10/100

Out of the last 13 quarters, TYRA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

LYEL
43/100

LYEL has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

TYRA
63/100

TYRA has had a higher than average amount of volatility over the last 12 months giving it a score of 63 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Lyell Immunopharma, Inc. Common Stock Summary

Nasdaq / LYEL

Healthcare

Biotechnology

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Tyra Biosciences, Inc. Common Stock Summary

Nasdaq / TYRA

Healthcare

Biotechnology

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Power up your portfolio